Volume 9 Issue 4 (April, 2021)

Original Articles

Biochemical Estimation of Serum Malondialdehyde and Superoxide Dismutase Levels in Oral Submucous Fibrosis Patients
Aabhi Shingala, Amit William, Radhika Thakkar, Fady Sadek, Amee Poshiya

Introduction: The most expected culprit of dysplastic changes in these lesions include the free radicals and reactive oxygen species that lead to lipid peroxidation. Early detection and knowledge of the dysplastic changes occurring in OSMF are helpful in prevention or progress of such lesions turning into oral cancer. Hence the aim was to estimate the serum superoxide dismutase (SOD) and serum Malondialdehyde (MDA) levels in patients with OSMF. Method: A total of 40 patients were included in the present study ranging between 18 to 75 years. Twenty OSMF cases which were clinically diagnosed were divided into different stages and grades respectively. Twenty healthy subjects without any habits and clinically normal appearing oral mucosa were included as controls. Serum MDA will be measured using the method of Ohkawa et al. and Serum Superoxide will be measured using the method of Fridvich and Mishra. Result: Serum MDA and serum SOD were compared within the clinical stages of OSMF patients. Comparison of MDA, SOD among the OSF group and control group showed statistically significant increased levels of malondialdehyde and decreased levels of superoxide dismutase among the OSF groups. Significant changes were not seen in MDA and SOD levels between the different grades of OSF. Conclusion: The present study showed significant increase in the serum MDA levels in all the clinical stage and histopathological grades, the maximum being in stage IV and Grade III. It was also observed a significant decrease in SOD levels in all the clinical stages of OSMF patients, the maximum being in stage IV and grade III. Key words: Malondialdehyde, Oral Cancer, Superoxide Dismutase, OSMF.

Abstract View | Download PDF | Current Issue

This work is licensed under a Creative Commons Attribution 3.0 License.